Skip to main content Skip to search Skip to main navigation
News: International

IPEC: Updated Position Paper on Third Party Audits

The International Pharmaceutical Excipients Council (IPEC) Federation has released an update of its position paper advocating for independent third party audits and certification programs. The position paper was first published in September 2015.

Key Highlights:

  • Regulatory and Industry Challenges: Increasing regulatory demands require pharmaceutical manufacturers to source excipients from reputable suppliers, placing a significant audit burden on both suppliers and users.
  • Third-Party Auditing Benefits: Independent audits improve impartiality, enhance GMP compliance, and reduce the need for repetitive audits by multiple customers.
  • Certification Standards: Third-party audits follow internationally recognized standards, such as ISO 17021 and ISO 17065, ensuring credibility and consistency.
  • Regulatory Alignment: Certification schemes align with regulatory requirements, including the EU’s Falsified Medicines Directive and the U.S. FDA’s Safety and Innovation Act.
  • Industry-Wide Efficiency: Adoption of third-party certification helps reduce costs, resources, and time for both excipient suppliers and users.

According to IPEC, the use of third-party audit and certification schemes helps to reduce costs, time and resources for both excipient suppliers and users. Such third-party audit and certification schemes both raise quality expectations to an industry-accepted level and improve patient safety.


Source:

IPEC: News


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
Previous
Next